The EU-ROP registry revolutionizes retinopathy of prematurity management, offering insights into treatment variations and outcomes across Europe. The management of retinopathy of prematurity (ROP) ...
Atrophy Advisor aids physicians in personalizing treatment for geographic atrophy in age-related macular degeneration, enhancing patient care and outcomes. Avery Kerwin, MD, the first author of the ...
Panelists discuss how the 8-mg aflibercept formulation improves drying efficacy, extends dosing intervals, and reduces burden while maintaining familiarity for patients across AMD and DME. This ...
Dr. Quan Dong Nguyen presents interim data from the phase 3 DRAGON study on a potential first therapy for adolescent Stargardt disease. Stargardt disease is a rare inherited retinal disorder that ...
Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...
Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection. The ideal syringe for administering intravitreal injections does not exist ...
Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics). Ahead of the Clinical Trials at the Summit (CTS) meeting in Las ...
How AI tools can drive early detection of diabetic eye conditions. Reviewed by T. Y. Alvin Liu, MD; Ariel Leong, MS; and Jane Huang, BS Led by T. Y. Alvin Liu, MD, a retinal specialist at the Johns ...
The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15. The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial.
The Vision Council’s Q3 Provider Insights study shows the sentiments of eye care providers nationwide as they manage practices and patient care. The Vision Council has released the results of their ...
The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...
A novel vascular endothelial growth factor receptor 2 (VEGF-R2) topical eye drop, PAN-90806 (PanOptica, Inc.), may revolutionize the treatment of neovascular age-related macular degeneration by making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback